Kidney Cancer Association
Unstoppable Together.

IKCS 2020:
A Virtual Experience

NOVEMBER 6–7, 2020
Table of Contents

Welcome Letter .......................................................................................................................2
About the Kidney Cancer Association ..................................................................................3
2020 Kidney Cancer Association Board of Directors ........................................................5
2020 Kidney Cancer Association Medical Steering Committee and Nursing Advisory Board ...............................................................6
Virtual Environment .............................................................................................................. 8
Maximizing Your Conference Experience ............................................................................11
Continuing Medical Education Information ...................................................................... 13
Agenda ...................................................................................................................................15
Scientific Planning Committee ...........................................................................................18
Faculty...................................................................................................................................20
Sponsors................................................................................................................................30
Poster Listings ......................................................................................................................31
Award Winners .....................................................................................................................35

We encourage all attendees to share their IKCS experience on social media. Make sure to add the hashtag #IKCS2020 and tag us @KidneyCancer in all your posts!

EARN. ENGAGE. WIN.

By participating in the IKCS 2020, you are eligible to win fun prizes! Earn points throughout the virtual experience by visiting exhibit booths, participating in poster presentations, attending sessions, and chatting with attendees. You can see how you are tracking against fellow attendees on the Leaderboard of the Virtual Experience. The attendees with the highest number of points by 4:00 PM EST on Saturday, November 7, 2020 will be entered to win complimentary registration to IKCS 2021 and other Kidney Cancer Association swag.
Welcome Letter

We are thrilled to welcome you to IKCS 2020: A Virtual Experience! The next two days promise an exciting program that showcases the best in kidney cancer research and discovery.

As a virtual experience, IKCS 2020 is a fun and interactive opportunity for participants from across the globe to join together and exchange ideas that will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure. You can also earn CME credits for attendance.

This year, we are proud to feature the 2019 Nobel Prize winner in Physiology or Medicine Dr. William G. Kaelin, Jr., who will give the IKCS 2020 keynote address, as well as two KCA career awardees – Dr. Steven Campbell of the Cleveland Clinic, who will give the Andrew C. Novick Memorial Lecture, and Dr. Axel Bex of the Royal Free NHS Foundation Trust in London, who will give the Pieter de Mulder Memorial Lecture.

We hope you’ll also enjoy the chance to test your knowledge of kidney cancer trivia, visit the exhibit hall, and participate in the not-to-be-missed Wood Fire session! As you share your thoughts and photos over social media, don’t forget to add the official hashtag: #IKCS2020.

2020 also marks the 30th anniversary of the KCA. As we look back on our origins as a small but dedicated group of patients and doctors in Chicago, Illinois, when a kidney cancer diagnosis meant facing a limited future, we should celebrate all we’ve accomplished together. Now, more than ever, it’s clear that the innovative work of healthcare professionals, scientists, industry partners, and patient advocates like you have helped propel us into a better future for those impacted by kidney cancer.

We would like to express our gratitude to those who worked diligently to make this virtual symposium a success including:

- Our presenters and panelists for sharing their expertise and insights;
- Our sponsors, exhibitors, and attendees, whose support made IKCS 2020 possible;
- Our Scientific Program Committee for their hours of hard work to craft a cutting-edge program – Chung-Han (Joe) Lee (Co-Chair), MD, PhD, Eric A. Singer, MD, MA, MS, FACS (Co-Chair), Matthew T. Campbell, MD, Vitaly Margulis, MD, Brad McGregor, MD, Brian Rini, MD, Laura Wood, RN, MSN, OCN and Tian Zhang, MD.

We are inspired by all you do in service of the kidney cancer community and we couldn’t be prouder to support you and help lead the way to a future cure for kidney cancer. Have a wonderful symposium!

Sincerely,

Gretchen E. Vaughan
President and CEO
Kidney Cancer Association

Christopher G. Wood, MD
Chairman, Board of Directors
Kidney Cancer Association

Bradley C. Leibovich, MD
Chair, Medical Steering Committee
Kidney Cancer Association

KIDNEY CANCER ASSOCIATION
9459 SW Gemini Drive #38269
Beaverton, OR 97008-7105
P 847-332-1051
Toll Free: 800-850-9132
office@kidneycancer.org

PRESIDENT AND CEO
Gretchen E. Vaughan

CHIEF ADVANCEMENT OFFICER
Kendall Monroe

BOARD OF DIRECTORS
Christopher G. Wood, MD, FACS, Chairperson
Craig DePriester, Vice Chairperson
Noah Buntman, Treasurer
Jamie Graves, Secretary
Lisa Alderson
Ronald M. Bukowski, MD
Tessa Churchill, MD, MBA
Bradley Leibovich, MD, FACS
Ryan Natzke
Eric Perakslis
David Perry, Esq.
William J. Perry
Denise L. Richards
Shelley Robson
Nicholas J. Vogelzang, MD
Laura Wood, RN, MSN, OCN
Ruben Ybarra

MEDICAL STEERING COMMITTEE
Bradley C. Leibovich, MD, Chairperson
Jose Karam, MD, FACS
Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
Chung-Han (Joe) Lee, MD, PhD
James Hsieh, MD, PhD
W. Kimryn Rathmell, MD, PhD
Brian Rini, MD, FASCO, Vice-Chairperson
Walter M. Stadler, MD, FACP, (Emeritus)
Nizar M. Tannir, MD, FACP
Christopher G. Wood, MD, FACS
**About the Kidney Cancer Association**

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

Our vision is to be the universal leader in finding the cure for kidney cancer.

Our mission is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

*One of the Association’s most important contributions is its support of the physicians and nurses who care for kidney cancer patients. Through our educational activities we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world’s leading technology and treatment options.*

—Gretchen E. Vaughan, President and CEO, Kidney Cancer Association

**MAIL DONATIONS TO:**

Kidney Cancer Association
9450 SW Gemini Drive #38269
Beaverton, OR 97008-7105
Tel: 847-332-1051
office@kidneycancer.org
See You in Edinburgh for EIKCS 2021

SAVE THE DATE
23–24, April 2021
Edinburgh, Scotland

Learn more at KCAMEETINGS.ORG
The Kidney Cancer Association would like to thank our 2020 Board Members!

BOARD OF DIRECTORS 2020

Lisa Alderson
Ronald M. Bukowski, MD
Noah Buntman
Tessa Churchill, MD, MBA
Craig DePriester
Jamie Graves
Bradley Leibovich, MD, FACS
Ryan Natzke
Eric Perakslis

David Perry, Esq.
William J. Perry
Denise L. Richards
Shelley Robson
Gretchen E. Vaughan
Nicholas J. Vogelzang, MD
Christopher G. Wood, MD, FACS (Chair)
Laura Wood, RN, MSN, OCN
Ruben Ybarra

Need more CME credits?
The Kidney Cancer Association is proud to offer free CME sessions to healthcare professionals interested in advancing their clinical knowledge in kidney cancer.

Learn more about our programs at KidneyCancer.org/cme-programming/
MEDICAL STEERING COMMITTEE 2020

Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
James Hsieh, MD, PhD
Jose Karam, MD, FACS
Chung-Han (Joe) Lee, MD, PhD
Bradley C. Leibovich, MD, FACS (Chair)
W. Kimryn Rathmell, MD, PhD
Brian Rini, MD (Vice-Chairperson)
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP
Christopher G. Wood, MD, FACS

CLINICAL ADVISORY BOARD 2020

Nancy Ainslie, RN, BSN
Julia Batten, APRN, MSN, MPH
Nina Decker, MSW, LCSW
Patricia Fisher, RN, MSN, ONC
Jan Jackson, RN
Kiran Kehoe, RN, BSN, CCRN
Zita Lim, PA-C
Nancy Moldawer, RN, MSN (Co-Chair)
Virginia J. Seery, MSN, RN, ANP-BC
Meghara Walsh, RN, BSN
Laura Wood, RN, MSN, OCN (Co-Chair)

Transforming patients’ lives through science™

We are in the business of breakthroughs—the kind that transform patients’ lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we’ll never give up our search for more hope, for more people, around the world.

We are proud to support the International Kidney Cancer Symposium.

Visit bms.com to see how we’re bringing a human touch to everything we do.

© 2020 Bristol-Myers Squibb Company. All rights reserved. NOUS2003642-01 10/20.
Oncogenes can reprogram tumor cell metabolism to depend on glutamine for proliferation and survival.\(^1\)

---

**Go to** [www.oncometabolism.com](http://www.oncometabolism.com) **to learn more.**

---

Calithera Biosciences – Our onco-metabolism approach brings an enhanced perspective to cancer.

CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc. © 2020 Calithera Biosciences, Inc. All rights reserved.

IKCS 2020 Virtual Environment

VIRTUAL LOBBY

Click here to visit over 10+ exhibitor booths, chat with exhibitors, and learn about their newest products and services.

Click here to chat with attendees, faculty, KOLs, exhibitors, and sponsors.

Click here for the educational sessions. Sessions will load daily and can be watched starting at the time they are scheduled for. Audience Q&A will be available after each presentation.

Click here for the virtual posters, to watch oral abstract presentations, and ask questions of the presenters.

Click here to join the Mentorship and Think Tank meetings.

Click here to view the Conference Guide, Agenda, Instructions for Navigating the Virtual Experience, or to get Customer Support.
2021 KCA Grants

Young Investigator Award (YIA) • Advanced Discovery Award (ADA)

MAR 1, 2021  Call for letters of intent (LOI)
APR 29, 2021  Final day to submit LOI
MAY 27, 2021  Final day that meritorious LOI proposals notified to proceed with full proposal
JUL 15, 2021  Final day to submit full proposals for academic review
SEP 21, 2021  Winning research teams notified

Learn more at KIDNEYCANCER.ORG
Maximizing Your Conference Experience

Here are some tips to make IKCS 2020 an enjoyable and educational experience. Registration is required to access presentations, sessions and ask questions of faculty.

GETTING THE MOST OUT OF THE CONFERENCE
1. Find a comfortable and quiet space to focus.
2. Plan to enter the conference 15 minutes before the first session to get familiar with navigating the virtual platform.
3. Plan ahead and choose the sessions you want to join in advance.
4. Have a notebook and pen handy to capture notes from each session.
5. You will join the conference using the link information provided to you via email a few days before the conference.
6. All presentations will take place in the Eastern Standard Time Zone.

ENSURE A SMOOTH CONNECTION TO THE CONFERENCE
If using a desktop or laptop computer, connect your device to a hard-wired Internet connection (not Wi-Fi) and running at high-speed. Ensure all applications or any programs with notifications, pop-ups or reminders are closed (e.g., Outlook, chat, calendar applications). Google Chrome is the preferred browser.

ACCESS TO PRESENTATIONS AND VIDEOS
All presentations and videos will be available to download on the KCAmeetings.org website approximately four weeks following the symposium. We will notify all IKCS 2020 participants when the program materials are on the site.

EXHIBIT HALL HOURS
The exhibit hall is accessible at any time during the conference. Visit the exhibit hall during scheduled break times or at your leisure to learn more about the latest and greatest products and services, while networking with industry leaders.
Exhibitors are available to chat with you to answer any questions you may have about their products and services. Many booths have downloadable resources and videos demonstrating their product lines.
Be sure to take advantage of the scroll/arrow function where you can easily visit the next booth.
Check out the IKCS 2020 exhibitors during the following break times:

**Friday, November 6**
12:00 PM – 1:15 PM EST
3:40 PM – 4:00 PM EST

**Saturday, November 7**
10:10 AM – 10:30 AM EST
12:30 PM - 1:00 PM EST

VIRTUAL POSTER HALL
The poster hall is accessible at any time during IKCS 2020. Visit our virtual posters in the poster hall and listen to the Uromigos Podcast broadcasting the latest developments in GU cancer on Friday, November 6 from 4:45 PM – 6:00 PM EST.
**THE CANCER IMMUNITY CYCLE**

Key processes in the cancer immunity cycle must be activated, engaged, and promoted for an anticancer immune response to lead to the effective killing of cancer cells.1

- **Release of cancer cell antigens**
- **Cancer antigen presentation**
- **Priming, proliferation, activation**
- **Infiltration of T cells into tumor**
- **Recognition of cancer cells by T cells**
- **Killing of cancer cells**

**BEMPEG (CD122-preferential agonist)**
- Primes, proliferates, activates, and increases tumor-infiltrating lymphocytes; increases PD-1 expression

**NKTR-255 (IL-15 receptor agonist)**
- Stimulates and expands NK cells; promotes survival and expansion of memory CD8+ T cells

**NKTR-262 (TLR 7/8 agonist)**
- Activates dendritic cell response

**NK cell**
- Stimulates and expands NK cells; promotes survival and expansion of memory CD8+ T cells

**NKTR-255 (IL-15RA)**
- Small-molecule therapy
- Cytokine therapy (IL-2 and IL-15)

**OUR IMMUNO-ONCOLOGY CLINICAL PIPELINE**

Nektar Therapeutics is developing novel immunotherapies that harness key steps in the cancer immunity cycle.1

### Preclinical Phase 1 Phase 2 Phase 3

<table>
<thead>
<tr>
<th>Partner</th>
<th>Indication</th>
<th>Program</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol Myers Squibb</td>
<td>Advanced renal cell carcinoma</td>
<td>BEMPEG + NIVO</td>
<td>NCT03729245</td>
<td>FDA Accelerated Approval registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Muscle-invasive bladder cancer</td>
<td>BEMPEG + NIVO</td>
<td>NCT04209114</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Metastatic prostate cancer</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT03785925</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Head and neck SCC</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT04640705</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>NSCLC</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT03635983</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>Head and neck SCC</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT04104445</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Advanced NSCLC</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT04052204</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Head and neck SCC</td>
<td>BEMPEG + Pembrolizumab</td>
<td>NCT04052204</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>vocoBody</td>
<td>Advanced solid tumors</td>
<td>NKTR-262 + BEMPEG</td>
<td>NCT03138889</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>vocoBody</td>
<td>R/R NHL or multiple myeloma</td>
<td>NKTR-262 + BEMPEG</td>
<td>NCT03548467</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>vocoBody</td>
<td>Head and neck SCC</td>
<td>NKTR-262 + BEMPEG</td>
<td>NCT03435640</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>vocoBody</td>
<td>Advanced melanoma</td>
<td>NKTR-262 + BEMPEG</td>
<td>NCT04136756</td>
<td>Registrational study</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BEMPEG, bempegaldesleukin (NKTR-214); IL, interleukin; NK, natural killer; PD-1, programmed death-1; TLR, toll-like receptor.**

Continuing Medical Education Information (CME) for IKCS 2020 is jointly provided by The France Foundation and the Kidney Cancer Association.

TARGET AUDIENCE
This educational activity is directed toward medical oncologists and urologists who treat patients with kidney cancer. Fellow, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

STATEMENT OF NEED
Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates and researchers to help promote learning and collaboration for advancement in the renal cancer space.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completion of this course, the participants should be able to:

1. Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma (RCC)
2. Identify the novel approaches to non-clear cell RCC trial design and patient management
3. Understand the role of metabolism as both a driver in RCC pathogenesis and as a target in its treatment

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians: The France Foundation designates this live virtual activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ethics: This course has been designated for 1.5 credit(s) of education in medical ethics and/or professional responsibility.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. Review the activity objectives and CME/CE information.
2. Participate in the CME/CE activity.
3. Complete the CME/CE evaluation form (which will be emailed to all participants who have accessed IKCS 2020 virtually), which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
4. Credit documentation/reporting:
   • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be made available for download.
   • If you are requesting medical ethics and/or professional responsibility credit, you will receive documentation that you can submit to your board.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

ACTIVITY STAFF DISCLOSURES

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the Kidney Cancer Association who control content have no relevant financial relationships to disclose.

FACULTY DISCLOSURES—ACTIVITY FACULTY

Please visit https://www.kcameetings.org/cme-information/.

DISCLOSURE OF UNLABELED USE

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

Please visit https://www.kcameetings.org/cme-information/.

DISCLAIMER

The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the Kidney Cancer Association, and the commercial supporter assume no liability for the information herein.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>Welcome to IKCS 2020</td>
</tr>
<tr>
<td></td>
<td>Andrew C. Novick Memorial Lecture</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>Partial Nephrectomy: An Ongoing Journey for Surgical Excellence</td>
</tr>
<tr>
<td></td>
<td><strong>Session 1:</strong> Multimodality Therapy for Locally Advanced Renal Cell Carcinoma (RCC)</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>Discussion of Multimodality Therapy</td>
</tr>
<tr>
<td>11:15 AM</td>
<td>Target Populations for Adjuvant/Perioperative Trials</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>Imaging End Points (RECIST versus irRECIST)</td>
</tr>
<tr>
<td>11:35 AM</td>
<td>Perioperative Trial Design Round Table</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Break</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Lunch — Satellite Symposium Session — Non CME</td>
</tr>
<tr>
<td></td>
<td>A Combination First-Line Treatment Option for Advanced Renal Cell Carcinoma (RCC)</td>
</tr>
<tr>
<td></td>
<td><strong>Session 2:</strong> Non-Clear Cell RCC</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Non-Clear Cell Trial Design Round Table</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>Discussion of Novel Approaches in Non-Clear Cell RCC</td>
</tr>
<tr>
<td></td>
<td><strong>Session 3:</strong> Immunotherapy and Emerging Therapies for RCC</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>Tyrosine Kinase Inhibitor/Immuno-oncology on Tumor Microenvironment</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Biomarkers for Immunotherapy</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>PARP Inhibitors for RCC</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>Discussion of Novel Approaches to Immunotherapy</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Break</td>
</tr>
<tr>
<td></td>
<td><strong>Session 4:</strong> Metabolism as a Target for RCC</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Metabolism as a Driver For RCC Discussion</td>
</tr>
<tr>
<td>4:25 PM</td>
<td>Adjourn</td>
</tr>
<tr>
<td>4:25 PM</td>
<td>Virtual Networking</td>
</tr>
<tr>
<td></td>
<td>Visit our Virtual Posters in the Poster Hall</td>
</tr>
<tr>
<td></td>
<td>Listen to Uromigos Podcast</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>KOL Discussion in Networking Lounge and Virtual Exhibit</td>
</tr>
<tr>
<td></td>
<td><strong>Topic 1:</strong> Brainstorm with Trainees and Junior Faculty on Developing the Next Generation of Kidney Cancer Researcher and Investigator-Initiated Trials</td>
</tr>
<tr>
<td></td>
<td><strong>Topic 2:</strong> Improving Access for Patients Through Social Media/Podcasts and Advocacy</td>
</tr>
<tr>
<td></td>
<td><strong>Topic 3:</strong> The Future of RCC Research</td>
</tr>
</tbody>
</table>

**Speakers**

- Chung-Han (Joe) Lee, MD, PhD and Eric A. Singer, MD, MA, MS, FACS
- Steven C. Campbell, MD, PhD

**Moderators:**

- Stephanie A. Berg, DO and Deborah R. Kaye, MD, MS
- Elizabeth Wulff-Burchfield, MD, Ivan Pedrosa, MD, PhD, Rahul A. Sheth, MD
- Naomi B. Haas, MD
- Rajan T. Gupta, MD
- Mohamad E. Allaf, MD, Naomi B. Haas, MD, Rajan T. Gupta, MD, Paul Russo, MD, FACS
- Amit Mehta, MD
- Maria I. Carlo, MD, Adam R. Metwalli, MD
- Darren Feldman, MD, Hyung L. Kim, MD, Bradley McGregor, MD, Brian Shuch, MD
- Mark W. Ball, MD, Aikseng Ooi, PhD, Jack Gleeson, MBBCh, MRCP, Matthew T. Campbell, MD, MS
- Katy Beckermann, MD, PhD, Eric C. Kaufman, MD
- Charles G. Drake, MD
- Timothy Chan, MD, PhD
- Vladimir Kolenko, MD, PhD
- Timothy Chan, MD, PhD, Charles G. Drake, MD, Vladimir Kolenko, MD, PhD
- Alex Chehrazi-Raffle, MD, Johanna C. Bendell, MD, Nizar M. Tannir, MD, FACP, Matthew D. Tucker, MD
- Gopal N. Gupta, MD, FACS, Tracy L. Rose, MD, MPH
- Laura Banaszynski, PhD, Ed Reznik, PhD, Nizar M. Tannir, MD, FACP, Shuchi Gulati, MD, MS, FACP
- Chung-Han (Joe) Lee, MD, PhD and Eric A. Singer, MD, MA, MS, FACS
- Nizar M. Tannir, MD, FACP
- Sumanta Kumar Pal, MD, Brian Rini, MD, FASCO, Thomas Powles, MD, MBBS, MRCP
- Chung-Han (Joe) Lee, MD, PhD, Eric A. Singer, MD, MA, MS, FACS
## Agenda

### Day 2  Saturday, November 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM EST</td>
<td>Breakfast — Satellite Symposium Session – Non CME CABOMETYX®: Treatment for Patients With Advanced Renal Cell Carcinoma</td>
<td>Daniel George, MD</td>
</tr>
<tr>
<td>8:00 AM EST</td>
<td>Welcome Day 2</td>
<td>Chung–Han (Joe) Lee, MD, PhD, Eric A. Singer, MD, MA, MS, FACS</td>
</tr>
<tr>
<td></td>
<td>Session 5: Multimodality Therapy for Metastatic Renal Cell Carcinoma (RCC)</td>
<td>Jason Abel, MD, FACS, Rana R. McKay, MD</td>
</tr>
<tr>
<td>8:05 AM EST</td>
<td>Pieter de Mulder Award Lecture Perioperative Treatment of Advanced RCC</td>
<td>Axel Bex, MD, PhD</td>
</tr>
<tr>
<td>8:35 AM EST</td>
<td>Immuno-oncology plus Immuno-oncology as 1st line Therapy</td>
<td>Ulka Vaishampayan, MD</td>
</tr>
<tr>
<td>8:50 AM EST</td>
<td>Tyrosine Kinase Inhibitor/Immuno-oncology as 1st line Therapy</td>
<td>Suzanne Cole, MD, FACP</td>
</tr>
<tr>
<td>9:05 AM EST</td>
<td>Discussion of First-Line therapy Open Forum and Q &amp; A</td>
<td>Laurence Albiges, MD, PhD (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guillermo de Velasco, MD, PhD (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Masatoshi Eto, MD, PhD (Japan)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>André P. Fay, MD, PhD (Brazil)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Viktor Grünwald, MD (Germany)</td>
</tr>
<tr>
<td>9:25 AM EST</td>
<td>International Considerations Panel</td>
<td></td>
</tr>
<tr>
<td>9:55 AM EST</td>
<td>International Considerations and Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>10:10 AM EST</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30 AM EST</td>
<td>Keynote Address: New Therapies for Kidney Cancer Based on Studies of the Von Hippel-Lindau Tumor Suppressor Gene</td>
<td>William G. Kaelin Jr., MD</td>
</tr>
<tr>
<td>11:00 AM EST</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session 6: Top Abstracts</td>
<td>Ardita Desai, MD, Abhishek Tripathi, MD</td>
</tr>
<tr>
<td>11:20 AM EST</td>
<td>Funding Mechanisms for RCC (Foundations and Governmental)</td>
<td>Eric Jonasch, MD</td>
</tr>
<tr>
<td>11:30 AM EST</td>
<td>Kidney Cancer Association Young Investigator Award #1</td>
<td>Pavlos Msaouel, MD, PhD</td>
</tr>
<tr>
<td>11:40 AM EST</td>
<td>Introduction to the Department of Defense Mentorship Program</td>
<td>Brian Rini, MD, FASCO</td>
</tr>
<tr>
<td>11:45 AM EST</td>
<td>Department of Defense Mentee #1</td>
<td>Abhishek A. Chakraborthy, PhD</td>
</tr>
<tr>
<td>11:50 AM EST</td>
<td>Department of Defense Mentee #2</td>
<td>Lucas A. Salas, MD, PhD, MPH</td>
</tr>
<tr>
<td>11:55 AM EST</td>
<td>Department of Defense Mentee #3</td>
<td>David A. Braun, MD, PhD</td>
</tr>
<tr>
<td>12:00 PM EST</td>
<td>Rapid Fire Top Abstracts Discussion</td>
<td>Brian Rini, MD, FASCO</td>
</tr>
<tr>
<td></td>
<td>Q &amp; A</td>
<td>Abhishek A. Chakraborthy, PhD</td>
</tr>
<tr>
<td>12:25 PM EST</td>
<td>Break</td>
<td>Lucas A. Salas, MD, PhD, MPH</td>
</tr>
<tr>
<td>12:30 PM EST</td>
<td>Lunch by the WoodFire</td>
<td>David A. Braun, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Moderator: Christopher G. Wood, MD, FACS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panelists: Thomas E. Hutson, DO, PharmD, FACP, Vitaly Margulis, MD, Sarah P. Pusatka, MD, MS, Tian Zhang, MD, MPS</td>
<td></td>
</tr>
<tr>
<td>1:40 PM EST</td>
<td>Closing Comments</td>
<td>Musatoishi Eto, MD, PhD (Japan)</td>
</tr>
<tr>
<td>1:45 PM EST</td>
<td>International Kidney Cancer Symposium/ Patient Joint Session: Treating Kidney Cancer in a Pandemic Discussion of Treating Kidney Cancer in a Pandemic</td>
<td>Matthew T. Campbell, MD, MS, William C. Huang, MD</td>
</tr>
<tr>
<td></td>
<td>Moderator: Matthew T. Campbell, MD, MS, William C. Huang, MD</td>
<td>Megan Conley, Brian M. Shinder, MD, Arnav Srivastava MD, MPH, Martin H. Voss, MD</td>
</tr>
<tr>
<td>2:30 PM EST</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
COMING SOON
OUR NEXT INDICATION

CABOMETYX

Sign up for updates by scanning the QR code or visiting
CABOMETYXnextindication.com

© 2020 Exelixis, Inc. CA-1806 10/20
Scientific Planning Committee

Chung-Han (Joe) Lee, MD, PhD, (Co-Chair)

Eric A. Singer, MD, MA, MS, FACS, (Co-Chair)

Matthew T. Campbell, MD

Vitaly Margulis, MD

Brad McGregor, MD

Brian Rini, MD (Mentorship Program Chair)

Laura Wood, RN, MSN, OCN

Tian Zhang, MD
MERCK IS PROUD TO BE A PART OF IKCS 2020

Click here to learn more
Faculty

Jason Abel, MD, FACS
University of Wisconsin
School of Medicine and
Public Health
Madison, WI

Laurence Albiges, MD, PhD
Gustave Roussy Institute
Villejuif, France

Mohamad E. Allaf, MD
Johns Hopkins Medicine
Baltimore, MD

Mark W. Ball, MD
National Cancer Institute,
National Institutes of Health
Bethesda, MD

Laura Banaszynski, PhD
Children’s Medical Center
Research Institute at UT
Southwestern
Dallas, Texas

Katy Beckermann, MD, PhD
Vanderbilt University
Medical Center
Nashville, TN

Johanna C. Bendell, MD
Sarah Cannon
Nashville, TN

Stephanie A. Berg, DO
Loyola University Chicago
Chicago, IL

Axel Bex, MD, PhD
The Netherlands Cancer
Institute
Amsterdam, The Netherlands
David A. Braun, MD, PhD
Dana-Farber Cancer Institute/
Harvard Medical School
Boston, MA

Matthew T. Campbell, MD, MS
The University of Texas MD
Anderson Cancer Center
Houston, TX

Steven C. Campbell, MD, PhD
Cleveland Clinic
Cleveland, OH

Maria I. Carlo, MD
Memorial Sloan Kettering
Cancer Center
New York, NY

Abhishek A. Chakraborty, PhD
Cleveland Clinic’s Lerner
College of Medicine
Cleveland, OH

Timothy Chan, MD, PhD
Memorial Sloan Kettering
Cancer Center
New York, NY

Alex Chehrazi-Raffle, MD
City of Hope
Los Angeles, CA

Suzanne Cole, MD, FACP
University Hospital Simmons
Comprehensive Cancer Clinic
Richardson, TX

Guillermo de Velasco, MD, PhD
LYX Urology Institute
Madrid, Spain
Faculty

Arpita Desai, MD
University of California, San Francisco
San Francisco, CA

Charles G. Drake, MD
Columbia University Irving Medical Center
New York, NY

Masatoshi Eto, MD, PhD
Kyushu University
Fukuoka, Japan

André P. Fay, MD, PhD
PUCRS School of Medicine
Brazil

Darren Feldman, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Jack Gleeson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Viktor Grünwald, MD
West German Cancer Center
Essen, Germany

Shuchi Gulati, MD, FACP
University of Cincinnati Cancer Center
Cincinnati, OH

Gopal N. Gupta, MD, FACS
Loyola University Health System
Chicago, IL
Faculty

Rajan T. Gupta, MD
Duke University Medical Center
Durham, NC

Naomi B. Haas, MD
Hospital of the University of Pennsylvania
Philadelphia, PA

William C. Huang, MD
NYU Langone Health
New York, NY

Thomas E. Hutson, DO, PharmD, FACP
Baylor University Medical Center
Dallas, TX

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

William G. Kaelin Jr, MD
2019 Nobel Laureate in Physiology or Medicine
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School Investigator
Howard Hughes Medical Institute
Boston, MA

Eric C. Kauffman, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Deborah R. Kaye, MD, MS
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Hyung L. Kim, MD
Cedars Sinai Medical Center
Los Angeles, CA
Faculty

Vladimir Kolenko, MD, PhD
Fox Chase Cancer Center
Philadelphia, PA

Chung-Han Lee, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Vitaly Margulis, MD
UT Southwestern Medical Center
Dallas, TX

Bradley McGregor, MD
Dana-Farber Cancer Institute
Boston, MA

Rana R. McKay, MD
University of California, San Diego
La Jolla, CA

Adam R. Metwalli, MD
Howard University Cancer Center
Washington, DC

Luis Meza, MD
City of Hope
Los Angeles, CA

Pavlos Msaouel, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, TX

Aiksgeng Ooi, PhD
University of Arizona
Tucson, Arizona
Faculty

Sumanta Kumar Pal, MD
City of Hope
Duarte, CA

Ivan Pedrosa, MD, PhD
UT Southwestern Medical Center
Dallas, TX

Thomas Powles, MD,
MBBS, MRCP
Barts Cancer Centre
London, England

Sarah P. Psutka, MD, MS
University of Washington
Seattle, WA

Ed Reznik, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Brian Rini, MD, FASCO
Professor of Medicine
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Nashville, TN

Tracy L. Rose, MD, MPH
University of North Carolina
Chapel Hill, NC

Paul Russo, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Lucas A. Salas, MD, PhD, MPH
Geisel School of Medicine at Dartmouth
Hanover, NH

Paul Russo, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
Faculty

Rahul A. Sheth, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Brian M. Shinder, MD
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Brian Shuch, MD
UCLA Kidney Cancer Program
Los Angeles, CA

Eric Singer, MD, MA, MS, FACS
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Arnav Srivastava, MD, MPH
Robert Wood Johnson Medical School
Rutgers University
New Brunswick, NJ

Nizar M. Tannir, MD, FACP
The University of Texas MD Anderson Cancer Center
Houston, TX

Abhishek Tripathi, MD
University of Oklahoma Stephenson Cancer Center
Oklahoma City, OK

Matthew D. Tucker, MD
Vanderbilt University Medical Center
Nashville, TN

Ulka Vaishampayan, MD
University of Michigan
Ann Arbor, MI
Faculty

Martin H. Voss, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Christopher G. Wood, MD, FACS
The University of Texas MD Anderson Cancer Center
Houston, TX

Elizabeth Wulff-Burchfield, MD
The University of Kansas Health System
Kansas City, KS

Yue Zhao, MBBS, MSc, PhD candidate
Francis Crick Institute
London, UK

Tian Zhang, MD
Duke Cancer Institute
Durham, NC
Now Enrolling Patients with Non-Muscle Invasive Bladder Cancer

Learn more here
A combination first-line treatment option for advanced renal cell carcinoma (RCC)

Friday, November 6, 2020
12:00 - 1:00 PM EST

This presentation will be given by:

Amit Mehta, MD
Medical Hematologist Oncologist
Premier Hematology & Oncology Center
Cary, North Carolina

Please visit the IKCS Congress Program website for additional information.

This Industry Theater presentation is not part of the scientific program as planned by the IKCS Program Committee. This event is neither sponsored nor endorsed by IKCS. This event does not qualify for continuing education credit. Sponsored by Pfizer.
IKCS 2020 is Made Possible with the Generous Support of:

- Pfizer Oncology
- Exelixis
- Bristol Myers Squibb
- Eisai
- EMD Serono
- Pfizer
- Merck
- Calithera
- Nektar
- Genentech
- Aveo Oncology
## Poster Listings

To view poster presentations during IKCS 2020, please visit the virtual poster hall.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Lead Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A phase 2 study of lenvatinib (LEN) plus everolimus (EVE) in patients with advanced non-clear cell renal cell carcinoma (nc-cRCC)</td>
<td>Thomas E. Hutson, DO, PharmD, FACP</td>
</tr>
<tr>
<td>2</td>
<td>A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk</td>
<td>Toni K. Choueiri, MD</td>
</tr>
<tr>
<td>3</td>
<td>A Phase 3, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab+Ipilimumab in Patients With Localized Renal Cell Carcinoma (RCC) at High Risk of Relapse After Radical or Partial Nephrectomy (CheckMate 914)</td>
<td>Axel Bex, MD, PhD</td>
</tr>
<tr>
<td>4</td>
<td>A pilot study of Tremelimumab with or without cryoablation in patients with metastatic renal cell carcinoma (mRCC): a post hoc analysis of patients with clear cell (cc) versus non-clear cell (ncc) histologies.</td>
<td>Matthew T. Campbell, MD, MS</td>
</tr>
<tr>
<td>5</td>
<td>A retrospective study of real-world treatment patterns and outcomes in advanced/metastatic renal cell carcinoma (a/mRCC) patients treated with lenvatinib+everolimus (Len/Eve) in a heavily pretreated population in the United States (US) community oncology setting</td>
<td>Nicholas J. Vogelzang, MD</td>
</tr>
<tr>
<td>6</td>
<td>An alternative to Open Data: Federated Machine Learning for Rare Kidney Cancer Across Data Silos While Enforcing Local Control</td>
<td>Anne Kim</td>
</tr>
<tr>
<td>7</td>
<td>An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution</td>
<td>Yue Zhao, MBBS, MSc, PhD candidate</td>
</tr>
<tr>
<td>8</td>
<td>Analysis of plasma circulating exosomes as a potential prognostic tool in renal cell carcinoma patients with brain metastasis.</td>
<td>Alberto Carretero Gonzalez</td>
</tr>
<tr>
<td>9</td>
<td>Association of the Neutrophil to Eosinophil Ratio with Response to Ipilimumab/Nivolumab in Metastatic Renal Cell Carcinoma</td>
<td>Matthew D. Tucker, MD</td>
</tr>
<tr>
<td>10</td>
<td>Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC)</td>
<td>Alex Chehazi-Raffle, MD</td>
</tr>
<tr>
<td>11</td>
<td>AURORAX-0087A, a multinational diagnostic study for detection of intermediate to high risk clear cell renal cell carcinoma: Trial in progress report</td>
<td>Saeed Dabestani</td>
</tr>
<tr>
<td>12</td>
<td>Bringing translational medicine to papillary renal cell carcinoma using deep learning</td>
<td>Reed Bender</td>
</tr>
<tr>
<td>13</td>
<td>Clinical IMPact of Early Progression among PAtients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) Treated with First-line (1L) Tyrosine Kinase Inhibitors (TKIs): IMPACT RCC Real-world Study</td>
<td>Thomas E. Hutson, DO, PharmD, FACP</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Lead Author</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>14</td>
<td>Clinical laboratory values associated with survival in patients with metastatic renal cell carcinoma: a Laboratory Wide Association Study (LWAS) approach</td>
<td>John Leppert</td>
</tr>
<tr>
<td>15</td>
<td>CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib vs cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma (RCC)</td>
<td>Sumanta Kumar Pal, MD</td>
</tr>
<tr>
<td>16</td>
<td>Correlative serum biomarker analyses: lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase 1b/2 trial in advanced renal cell carcinoma (RCC)</td>
<td>Chung-Han Lee, MD, PhD</td>
</tr>
<tr>
<td>17</td>
<td>Delaying Surgery for Clinical T1b-T2bN0M0 Renal Cell Carcinoma: Oncologic Implications in the COVID-19 Era and Beyond</td>
<td>Arnav Srivastava, MD, MPH</td>
</tr>
<tr>
<td>18</td>
<td>Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101</td>
<td>Martin H. Voss, MD</td>
</tr>
<tr>
<td>19</td>
<td>Associations between serum cytokine levels and gut microbiota composition in metastatic renal cell carcinoma</td>
<td>Alex Chehrazi-Raffle, MD</td>
</tr>
<tr>
<td>20</td>
<td>Factors associated with clinical trial participation for patients with renal cell carcinoma</td>
<td>Brian M. Shinder, MD</td>
</tr>
<tr>
<td>21</td>
<td>Factors Associated with Palliative Care Utilization in Advanced and Metastatic Renal Cell Carcinoma</td>
<td>Hiren V. Patel</td>
</tr>
<tr>
<td>22</td>
<td>Metabolic gene signature as biomarker for recurrence in localized clear cell RCC</td>
<td>Shuchi Gulati</td>
</tr>
<tr>
<td>23</td>
<td>MK-6482, a Hypoxia-Inducible Factor 2α Inhibitor, Versus Everolimus in Heavily Pretreated, Immune Checkpoint Inhibitor–Resistant, Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Phase 3 Study</td>
<td>Toni K. Choueiri, MD</td>
</tr>
<tr>
<td>24</td>
<td>Nivolumab 6 mg/kg plus ipilimumab 1 mg/kg (N6I1) every 8 weeks (Q8W) alternating with nivolumab 480 mg Q8W for first-line (1L) advanced renal cell carcinoma (aRCC): safety and efficacy from CheckMate 920</td>
<td>Johanna C. Bendell, MD</td>
</tr>
<tr>
<td>25</td>
<td>Nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in first-line treatment for advanced renal cell carcinoma (aRCC): the phase 3 CheckMate 9ER trial</td>
<td>Andrea Apolo</td>
</tr>
<tr>
<td>26</td>
<td>Nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy</td>
<td>Nizar M. Tannir, MD, FACP</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Lead Author</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>27</td>
<td>Open-Label Phase 2 Study of Two Doses of MK-6482 for the Treatment of Advanced Renal Cell Carcinoma Following Progression on Prior Systemic Therapy</td>
<td>Michael B. Atkins</td>
</tr>
<tr>
<td>28</td>
<td>Oral HIF-2α Inhibitor MK-6482 for von Hippel–Lindau Disease (VHL)–Associated Clear Cell Renal Cell Carcinoma (ccRCC)</td>
<td>Vivek K. Narayan</td>
</tr>
<tr>
<td>29</td>
<td>Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity</td>
<td>Frede Donskov</td>
</tr>
<tr>
<td>30</td>
<td>Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC): Subgroup Analysis From KEYNOTE-426 by Prior Nephrectomy</td>
<td>Denis Soulières</td>
</tr>
<tr>
<td>31</td>
<td>Phase 1/2 Study of the Oral HIF-2α Inhibitor MK-6482 in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)</td>
<td>Elizabeth R. Plimack, MD, MS</td>
</tr>
<tr>
<td>32</td>
<td>Phase 2 trial of lenvatinib + pembrolizumab for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review (IIR) and subgroup analyses</td>
<td>Chung-Han Lee, MD, PhD</td>
</tr>
<tr>
<td>33</td>
<td>Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)</td>
<td>Sumanta Kumar Pal, MD</td>
</tr>
<tr>
<td>34</td>
<td>Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer</td>
<td>Sandeep Gurram</td>
</tr>
<tr>
<td>35</td>
<td>Prolyl hydroxylase 3 knockdown accelerates VHL-mutant kidney cancer growth in vivo</td>
<td>Niki Zacharias Millward</td>
</tr>
<tr>
<td>36</td>
<td>Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) of Lenvatinib+Everolimus vs Everolimus Monotherapy in Advanced Renal Cell Carcinoma (aRCC)</td>
<td>Chung-Han Lee, MD, PhD</td>
</tr>
<tr>
<td>37</td>
<td>Radiomic features of renal cell carcinoma metastatic sites can predict BAP1 mutation</td>
<td>Luis Meza, MD</td>
</tr>
<tr>
<td>38</td>
<td>Real-world clinical effectiveness of lenvatinib+everolimus (Len/Eve) in a heavily pre-treated advanced/metastatic renal cell carcinoma (a/mRCC) population in the US community oncology setting: a retrospective chart review study</td>
<td>Nicholas J. Vogelzang, MD</td>
</tr>
<tr>
<td>39</td>
<td>Real-World Referral and Adjuvant Treatment Patterns in High-Risk Locoregional Renal Cell Carcinoma</td>
<td>Hannah Dzmitrowicz</td>
</tr>
<tr>
<td>40</td>
<td>Reassuring RECIST v1.1 defined progression by Dynamic Contrast-Enhanced Computed Tomography in metastatic renal cell carcinoma</td>
<td>Aska Driljevic-Nielsen</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Lead Author</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>41</td>
<td>Response to Systemic Therapy in Patients with Metastatic Fumarate Hydratase (FH) Deficient Renal Cell Carcinoma</td>
<td>Jack Gleeson, MBBCh, MRCPI</td>
</tr>
<tr>
<td>42</td>
<td>Retrospective assessment of gastrointestinal tract metastasis from large cohort of metastatic renal cell cancer.</td>
<td>Rony Maelle</td>
</tr>
<tr>
<td>43</td>
<td>The Impact of Venous Thromboembolism Presence at the Time of Nephrectomy for Renal Cell Carcinoma on Complications, Costs, and Survival</td>
<td>Hiren V. Patel, MD, PhD</td>
</tr>
</tbody>
</table>

**MERIT AWARD WINNERS FOR TOP ABSTRACTS**

1st place: Arnav Srivastava, MD, MPH for Delaying Surgery for Clinical T1b-T2bN0M0 Renal Cell Carcinoma: Oncologic Implications in the COVID-19 Era and Beyond

2nd place: Jack Gleeson, MBBCh, MRCPI for Response to Systemic Therapy in Patients with Metastatic Fumarate Hydratase (FH) Deficient Renal Cell Carcinoma

3rd place: Alex Chehrazi-Raffle, MD for Associations between serum cytokine levels and gut microbiota composition in metastatic renal cell carcinoma
Congratulations To Our Award Winners:

The Andrew C. Novick Award is proudly presented to Steven C. Campbell, MD, PhD for his outstanding contributions to kidney cancer at the Nineteenth International Kidney Cancer Symposium, November 6, 2020.

The Pieter de Mulder Award is proudly presented to Axel Bex, MD, PhD for his outstanding contributions to renal cell carcinoma at the Nineteenth International Kidney Cancer Symposium, November 7, 2020.

Click here to learn more about a guideline-recommended treatment for your advanced RCC patients.
See You in Austin for IKCS 2021

SAVE THE DATE
November 5–6, 2021
Austin, Texas

Learn more at KCAMEETINGS.ORG